Meeting
2020 Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and irinotecan as third-line chemotherapy for advanced gastric cancer: A multi-institutional retrospective study.
Authors
Ryosuke Kumanishi
Aichi Cancer Center Hospital, Nagoya City, Japan
Ryosuke Kumanishi , Seiichiro Mitani , Shigenori Kadowaki , TOMOHIRO MATSUSHIMA , Naoki Takahashi , Takatsugu Ogata , Hisateru Yasui , Misato Ogata , Hironaga Satake , Yukiya Narita , Toshiki Masuishi , Hideaki Bando , Hiroki Hara , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 396)
Abstract #
396
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.
First Author: Keitaro Shimozaki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A scoring system for selecting nivolumab or irinotecan in the later-line chemotherapy for advanced gastric cancer: A Japanese multicenter retrospective study.
First Author: Yusuke Amanuma
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and early efficacy results of a phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study).
First Author: Daisuke Takahari
Poster
2022 ASCO Gastrointestinal Cancers Symposium
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).
First Author: Tomohiro Matsushima